Alexander Schacht
Research Subjects
Alexander Schacht has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Gerd Lehmkuhl
Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters der Universität zu Köln
1 shared publication - Inmaculada Gilaberte
Takeda Madrid, Cell Therapy Technology Center, Tres Cantos, Madrid, Spain
1 shared publication - Irene Romera
Eli Lilly and Company, Madrid, Spain
1 shared publication - Jenny Devenport
F Hoffman‐La Roche Basel Switzerland
1 shared publication - Josep Manuel Menchón
Psychiatry and Mental Health Group, Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain
1 shared publication - Karin Helsberg
Lilly Deutschland, Medical Department, Bad Homburg, Germany
1 shared publication
Latest Publications
- 11 July 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (6) , 1135-1140
Leading beyond regulatory approval: Opportunities for statisticians to optimize evidence generation and impact clinical practice
The role and value of statistical contributions in drug development up to the point of health authority approval are well understood. But health authority approval is only a true 'win' if the evidence enables access and adoption into clinical practice. In today's complex and evolving healthcare environment, there is additional strategic evidence generation, communication, and decision support that can benefit from statistical contributions. In this article, we describe the history of medical affairs in the context of drug development, the factors driving post-approval evidence generation needs, and the opportunities for statisticians to optimize evidence generation for stakeholders beyond health authorities in order to ensure that new medicines reach appropriate patients.
- 11 July 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (6) , 1135-1140
Leading beyond regulatory approval: Opportunities for statisticians to optimize evidence generation and impact clinical practice
The role and value of statistical contributions in drug development up to the point of health authority approval are well understood. But health authority approval is only a true 'win' if the evidence enables access and adoption into clinical practice. In today's complex and evolving healthcare environment, there is additional strategic evidence generation, communication, and decision support that can benefit from statistical contributions. In this article, we describe the history of medical affairs in the context of drug development, the factors driving post-approval evidence generation needs, and the opportunities for statisticians to optimize evidence generation for stakeholders beyond health authorities in order to ensure that new medicines reach appropriate patients.
- 1 April 2013
- Published by Elsevier in Journal of Affective Disorders
- Vol. 146 (3) , 433-437
Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD
- 1 April 2013
- Published by Elsevier in Journal of Affective Disorders
- Vol. 146 (3) , 433-437
Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD
- Open Access
- 9 February 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 5
Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies
The impact of once daily atomoxetine treatment on symptoms in children and adolescents with ADHD may vary over the day. In order to capture such variations, two studies were undertaken in children and adolescents with ADHD using two instruments that capture morning and evening behavior and ADHD-related difficulties over the day. This secondary measure analysis builds on two primary analyses that were conducted separately for children and adolescents and also published separately.
- 9 February 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 5
Open AccessMorning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies
The impact of once daily atomoxetine treatment on symptoms in children and adolescents with ADHD may vary over the day. In order to capture such variations, two studies were undertaken in children and adolescents with ADHD using two instruments that capture morning and evening behavior and ADHD-related difficulties over the day. This secondary measure analysis builds on two primary analyses that were conducted separately for children and adolescents and also published separately.